In conclusion, the current study identified a previously uncharacterized OGT-mediated KEAP1/NRF2 axis that influences VC in CKD settings and revealed a potential treatment strategy to prevent or treat cardiovascular complications associated with CKD. This evidence concerns the gene NFE2L2 and chronic kidney disease.